TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Klotho Neurosciences ( (KLTO) ) has provided an announcement.
On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug Designation to its KLTO-202 for the treatment of Amyotrophic Lateral Sclerosis (ALS). This designation provides incentives like tax credits for clinical trials and seven years of market exclusivity. The company’s lead product candidate, KLTO-202, targets motor neuron diseases and muscular dystrophies, aiming to deliver gene therapy to the neuromuscular junction. This FDA recognition is seen as validation of Klotho’s scientific approach and could significantly impact its market positioning in the treatment of rare neurodegenerative diseases.
More about Klotho Neurosciences
Klotho Neurosciences, Inc. is a biogenetics company specializing in the development of innovative cell and gene therapies aimed at treating neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company utilizes a protein derived from a patented form of the human Klotho gene and novel delivery systems to create disease-modifying therapies. Their portfolio includes cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays.
Average Trading Volume: 43,251,282
Technical Sentiment Signal: Buy
Current Market Cap: $70.62M
Learn more about KLTO stock on TipRanks’ Stock Analysis page.